Logo
x

Search category

Subscribe Now

Europe

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis...

  • September 17, 2021
Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis...

  • September 17, 2021
Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

  • July 2, 2021
Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

  • July 2, 2021
PharmaShots Interview: GSK's Mike Crichton Shares Insights on the Approval of Benlysta in Europe

PharmaShots Interview: GSK's Mike Crichton Shares Insights on the Approval of Benlysta in Europe

  • June 8, 2021
PharmaShots Interview: GSK's Mike Crichton Shares Insights on the Approval of Benlysta in Europe

PharmaShots Interview: GSK's Mike Crichton Shares Insights on the Approval of Benlysta in Europe

  • June 8, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.